Integrated BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INBP research report →
Price Chart
About the company
Integrated BioPharma, Inc. , together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines.
- CEO
- Riva Sheppard
- IPO
- 1996
- Employees
- 134
- HQ
- Hillside, NJ, US
Get TickerSpark's AI analysis on INBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.75M
- P/E
- -2.02
- PEG
- 0.04
- P/S
- 0.13
- P/B
- 0.33
- EV/EBITDA
- -3.20
- Div Yield
- 0.00%
- Gross Margin
- 1.82%
- Op Margin
- -6.17%
- Net Margin
- -6.48%
- ROE
- -14.78%
- ROIC
- -13.04%
Latest fiscal year · YoY change
- Revenue
- $43.87M-19.3%
- Gross Profit
- $800.00K-85.6%
- Op Income
- $-2,705,000
- Net Income
- $-2,842,000-451.7%
- EPS
- $-0.09-442.7%
- OCF Growth
- -39.9%
- FCF Growth
- -52.2%
- 52W High
- $0.42
- 52W Low
- $0.14
- 50D MA
- $0.17
- 200D MA
- $0.24
- Beta
- 0.40
- RSI (14)
- 54
- Avg Volume
- 9.43K
No earnings-call transcripts are available for INBP yet.
- Free Float
- 30.1%
- Shares Outstanding
- 31.06M
- Float Shares
- 9.34M
of shares held by institutions
1 13F filers
Buy/sell ratio 1.75. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Moloney Securities Asset Management, LLC | 20.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 24, 26 | Friedman Eric J | other | 50,000 |
| Jun 24, 26 | DeSantis Damon | other | 50,000 |
| Jun 24, 26 | Friedman Eric J | other | 50,000 |
| Jun 24, 26 | Canarick Robert | other | 50,000 |
| Jun 24, 26 | Milmoe William H. | other | 50,000 |
| Apr 15, 26 | Milmoe William H. | other | 8,966,547 |
| Apr 15, 26 | Milmoe William H. | other | 2,235,417 |
| Apr 15, 26 | DESANTIS CARL | other | 8,966,547 |
| Apr 15, 26 | DESANTIS CARL | other | 2,235,417 |
| Apr 15, 26 | DeSantis Damon | other | 2,235,417 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INBP coverage
Recent articles, reports, and earnings notes.
No research on INBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INBP report →Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026
accessnewswire.com · Sep 25
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026
accessnewswire.com · May 8
Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025
accessnewswire.com · Feb 11
Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions
globenewswire.com · Dec 2
Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025
accessnewswire.com · Nov 10
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025
accessnewswire.com · Sep 23
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025
accessnewswire.com · May 14
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024
accessnewswire.com · Feb 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.